Pfizer starts process for U.S. approval of COVID-19 booster shot

FILE PHOTO: Vials of Pfizer’s coronavirus disease (COVID-19) vaccine are seen at a pop-up community vaccination center at the Gateway World Christian Center in Valley Stream, New York, U.S., February 23, 2021. REUTERS/Brendan McDermid/File Photo

(Reuters) – Pfizer Inc and BioNTech have started the process for a full approval of a booster dose of their COVID-19 vaccine in people aged 16 years and older, the drugmakers said on Wednesday.

The companies intend to complete the submission by the end of this week. This could potentially pave the way for a third dose that can be offered to people with compromised immune systems.

U.S. officials have said that COVID-19 vaccine booster shots will be made widely available to Americans starting Sept. 20.

Earlier this week, U.S. regulators granted full approval to the two-dose vaccine based on updated data from the companies’ clinical trial and manufacturing review.

A third dose of the Pfizer-BioNTech vaccine is not currently authorized for broad use in the United States. However, under the amended Emergency Use Authorization, a third dose was authorized for administration to individuals at least 12 years of age who were immunocompromised.

Source: Read Full Article

Related posts:
  1. Same efficiency of AstraZeneca and Pfizer shots in severe COVID cases: French infectiologist
  2. White House knew of J&J vaccine contamination problems last week
  3. Hungary in talks to plug expected shortfall in COVID-19 vaccine deliveries
  4. AstraZeneca ceo says committed to supply COVAX, calls for open borders
  5. Vaccine waiver talks a chance for WTO to show its relevance: U.S. trade chief Tai